Edition:
United States

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

48.89USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$48.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
352,398
52-wk High
$49.85
52-wk Low
$12.62

Select another date:

Tue, May 8 2018

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018

BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8

* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:

BRIEF-Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering

* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Arena Pharma's bowel disease drug meets study goal, shares surge

Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

UPDATE 1-Arena Pharma's bowel disease drug meets study goal, shares surge

March 19 Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

BRIEF-Arena Pharmaceuticals Q4 Loss Per Share $0.35

* ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Select another date: